Transcriptomics and experimental validation-based approach to understand the effect and mechanism of Huangqin tang interfeience with colitis associated colorectal cancer.
Azoxymethane/dextran sodium sulfate model
Colitis-associated colorectal cancer
Epithelial mesenchymal transition
Pyroptosis
Transcriptome
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
21
11
2022
revised:
04
02
2023
accepted:
10
02
2023
entrez:
17
3
2023
pubmed:
18
3
2023
medline:
18
3
2023
Statut:
epublish
Résumé
Chronic inflammation is usually caused by persistent irritation or uncontrolled infection and is characterized by ongoing tissue damage, injury-induced cellular proliferation and tissue repair. Colitis-associated colorectal cancer (CAC) isone of the classic examples of tumors that are tightly related to chronic inflammation. To investigated the key pharmacodynamic genes of HQT interventions in CAC by using transcriptome predictions and experiments.Materials & Methods: We used the azoxymethane/dextran sodium sulfate method to induce the mice CAC model. After preventive administration of HQT to the mice model, colonic tissues were taken for transcriptome sequencing and the transcriptome results were then experimentally validated using quantitative Real-Time PCR technique. Transcriptome sequencing revealed that the effect of the mechanism of HQT on the CAC mice model maybe related to its inhibition of accelerated epithelial mesenchymal transition and induction of pyroptosis. The levels of Matrix-metalloproteinases such as MMP-2, MMP-9 were significantly reduced in CAC mice treated with HQT; The mRNA expression for Krt17, App, CD44 and WNT pathway related sites such as Lrrc15, Cldn-1, Mpc1, Agr2 which are related factors affecting the epithelial mesenchymal transition were significantly reduced in CAC mice treated with HQT; the aberrant mRNA expression of inflammasome components that drive pyroptosis, including Nlrp3, Caspase-1, ASC, GSDMD and its mediated product IL-18 have been improved. Our findings provide preliminary clarification that inhibiting the progression of CAC by using HQT is effective, the mechanism of action may be relatedto the inhibition of epithelial mesenchymal transition and induction of pyroptosis during tumorigenesis.
Sections du résumé
Context
UNASSIGNED
Chronic inflammation is usually caused by persistent irritation or uncontrolled infection and is characterized by ongoing tissue damage, injury-induced cellular proliferation and tissue repair. Colitis-associated colorectal cancer (CAC) isone of the classic examples of tumors that are tightly related to chronic inflammation.
Background
UNASSIGNED
To investigated the key pharmacodynamic genes of HQT interventions in CAC by using transcriptome predictions and experiments.Materials & Methods: We used the azoxymethane/dextran sodium sulfate method to induce the mice CAC model. After preventive administration of HQT to the mice model, colonic tissues were taken for transcriptome sequencing and the transcriptome results were then experimentally validated using quantitative Real-Time PCR technique.
Results
UNASSIGNED
Transcriptome sequencing revealed that the effect of the mechanism of HQT on the CAC mice model maybe related to its inhibition of accelerated epithelial mesenchymal transition and induction of pyroptosis. The levels of Matrix-metalloproteinases such as MMP-2, MMP-9 were significantly reduced in CAC mice treated with HQT; The mRNA expression for Krt17, App, CD44 and WNT pathway related sites such as Lrrc15, Cldn-1, Mpc1, Agr2 which are related factors affecting the epithelial mesenchymal transition were significantly reduced in CAC mice treated with HQT; the aberrant mRNA expression of inflammasome components that drive pyroptosis, including Nlrp3, Caspase-1, ASC, GSDMD and its mediated product IL-18 have been improved.
Conclusions
UNASSIGNED
Our findings provide preliminary clarification that inhibiting the progression of CAC by using HQT is effective, the mechanism of action may be relatedto the inhibition of epithelial mesenchymal transition and induction of pyroptosis during tumorigenesis.
Identifiants
pubmed: 36925536
doi: 10.1016/j.heliyon.2023.e13739
pii: S2405-8440(23)00946-5
pmc: PMC10011003
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e13739Informations de copyright
© 2023 Published by Elsevier Ltd.
Références
J Clin Endocrinol Metab. 2011 Mar;96(3):E554-65
pubmed: 21190978
Histol Histopathol. 2018 Oct;33(10):1013-1019
pubmed: 29504115
Neoplasia. 2019 Jan;21(1):106-116
pubmed: 30530053
Eur J Cell Biol. 2000 Dec;79(12):905-14
pubmed: 11152291
BMC Cancer. 2020 Jan 10;20(1):28
pubmed: 31924176
Oncol Res. 2001;12(11-12):469-76
pubmed: 11939410
Science. 2012 Jul 6;337(6090):96-100
pubmed: 22628558
Nat Rev Cancer. 2019 Apr;19(4):197-214
pubmed: 30842595
Dis Model Mech. 2015 Aug 1;8(8):817-29
pubmed: 26044960
J Clin Oncol. 2014 Aug 20;32(24):2562-9
pubmed: 25071101
Evid Based Complement Alternat Med. 2020 Apr 22;2020:1874065
pubmed: 32382278
Oncotarget. 2016 Aug 2;7(31):49180-49193
pubmed: 27341132
Immunity. 2019 Jun 18;50(6):1352-1364
pubmed: 31216460
Nat Med. 2006 May;12(5):568-73
pubmed: 16648858
Int J Mol Sci. 2019 Oct 07;20(19):
pubmed: 31591367
Cell. 2010 Mar 19;140(6):821-32
pubmed: 20303873
Front Immunol. 2020 Jul 08;11:1444
pubmed: 32733479
Exp Biol Med (Maywood). 2013 Mar;238(3):324-38
pubmed: 23598979
J Invest Dermatol. 1997 Mar;108(3):324-9
pubmed: 9036933
Acta Pharm Sin B. 2016 Mar;6(2):148-57
pubmed: 27006899
Cancer Res. 2018 Jul 15;78(14):4059-4072
pubmed: 29764866
Cell. 1995 May 19;81(4):525-31
pubmed: 7758106
Lancet Oncol. 2021 Aug;22(8):e358-e368
pubmed: 34339656
PLoS One. 2012;7(6):e37174
pubmed: 22719836
Curr Biol. 2000 Dec 14-28;10(24):1603-6
pubmed: 11137014
Gastroenterology. 2001 May;120(6):1356-62
pubmed: 11313305
Front Pharmacol. 2022 Apr 06;13:837217
pubmed: 35462890
Nat Rev Mol Cell Biol. 2019 Feb;20(2):69-84
pubmed: 30459476
Cancers (Basel). 2020 Mar 23;12(3):
pubmed: 32210091
J Mater Sci Mater Med. 2010 Feb;21(2):551-6
pubmed: 19921404
Future Oncol. 2020 Nov;16(32):2619-2633
pubmed: 32804554
Science. 2018 Nov 30;362(6418):1064-1069
pubmed: 30361383
Cancer Discov. 2020 Feb;10(2):232-253
pubmed: 31699795
Oncogene. 1999 Feb 18;18(7):1435-46
pubmed: 10050880
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
Gut. 2017 Apr;66(4):683-691
pubmed: 26818619
Nat Immunol. 2016 Mar;17(3):230-40
pubmed: 26882261
Genes Dev. 2002 Dec 1;16(23):3074-86
pubmed: 12464636
Cancer Res. 2008 Apr 15;68(8):2551-6
pubmed: 18413720
Nat Med. 2015 Aug;21(8):906-13
pubmed: 26107252
Immunity. 2012 Feb 24;36(2):215-27
pubmed: 22365665
J Cell Biol. 2000 Sep 4;150(5):1071-84
pubmed: 10973996
Br J Cancer. 2014 Mar 18;110(6):1413-9
pubmed: 24569467
Gastrointest Cancer Res. 2011 Mar;4(2):53-61
pubmed: 21673876
Nature. 2016 Jul 7;535(7610):111-6
pubmed: 27281216
Mol Med Rep. 2022 Jan;25(1):
pubmed: 34726255